Abstract
Background The presence of myocardial late gadolinium enhancement (LGE) in patients with sarcoidosis is a powerful predictor of major adverse events (MAE: death, ventricular tachycardia, or appropriate ICD therapy). In this study, we aim to determine if the burden of LGE, left ventricular (LV) and right ventricular (RV) end-diastolic and end-systolic volume index (EDVi & ESVi) and ejection fraction (EF) can be used to improve risk stratification in patients with cardiac sarcoidosis (CS). Methods We identified 25 consecutive subjects with a diagnosis of CS (biopsy-proven extra-cardiac sarcoidosis and presence of LGE on cardiovascular magnetic resonance). Imaging was performed on a 1.5T scanner. Short axis cines (6 mm thickness, 4 mm gap, temporal resolution 5 standard deviations above the mean SI of normal remote myocardium. The total amount of LGE as a percentage of LV mass (%LGE) was determined using Diagnosoft Virtue software (Figure 1). Medical records were reviewed to identify MAE. Area under the curve (AUC) was determined from receiver-operator characteristics demonstrating the ability of %LGE, LVEDVi, LVESVi, LVEF, RVEDVi, RVESVi, and RVEF to detect MAE. Patients were divided into 2 groups; with MAE and without MAE. Each parameter was evaluated using unpaired T-tests. Continuous variables are presented as mean ± standard deviation. Results The mean age was 58 ±7y ears, 18 (72%) were female. Mean follow up was 39 ± 15 months. Six (24%) of patients had MAE. There was a significant difference in %LGE, RVEF and RVESVi but not LVEF, LVESVi, LVEDVi or RVEDVi between those who had MAE and those who did not (Table 1). The AUC for each of the following parameter’s ability to predict MAE was: LVEF 0.54, LVEDVi 0.58, LVESVi 0.62, LGE 0.67, RVEDVi 0.76, RVESVi 0.85, and RVEF 0.56. Notably, in terms of predicting death, the AUC for %LGE, RVEDVi and RVESVi were high at 0.87, 0.86 and 0.89 respectively, while that for LVEF was 0.61, RVEF 0.61, LVEDVi 0.54 and LVESVi 0.55. Conclusions The burden of LGE and RV size and function (not LV size and function) further improve prediction of death and significant ventricular arrhythmia in patients with cardiac sarcoidosis Funding None.
Highlights
The presence of myocardial late gadolinium enhancement (LGE) in patients with sarcoidosis is a powerful predictor of major adverse events (MAE: death, ventricular tachycardia, or appropriate ICD therapy)
We aim to determine if the burden of LGE, left ventricular (LV) and right ventricular (RV) end-diastolic and end-systolic volume index (EDVi & ESVi) and ejection fraction (EF) can be used to improve risk stratification in patients with cardiac sarcoidosis (CS)
We identified 25 consecutive subjects with a diagnosis of CS
Summary
Refining risk assessment in cardiac sarcoidosis: a role for burden of late gadolinium enhancement and right ventricular function. Gillian Murtagh*, Karima Addetia, Amit Patel, Luke Laffin, Francesco Maffessanti, John F Beshai, Roberto Lang, Victor Mor-Avi, Amit R Patel. From 17th Annual SCMR Scientific Sessions New Orleans, LA, USA. From 17th Annual SCMR Scientific Sessions New Orleans, LA, USA. 16-19 January 2014
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.